Hyderabad: Mapmygenome, India’s leading AI-powered genomics and personalized health company, has announced the acquisition of Microbiome Insights, a globally recognized microbiome sequencing and analytics firm based in Canada.
The strategic acquisition marks a pivotal step in Mapmygenome’s global expansion, significantly enhancing its capabilities in microbiome research, metagenomics, and precision health diagnostics.
This move also brings under Mapmygenome’s fold a CAP-accredited laboratory and a robust portfolio of intellectual property assets, further establishing the company’s position as a global leader in genomics.
Founded by renowned scientists Dr Brett Finlay, Dr William Mohn, and Malcolm Kendall, Microbiome Insights has supported over 1,000 projects across 600+ clients in the academic, clinical, and biotech research communities. The company is well-regarded for its expertise in microbial sequencing, metagenomics, and microbiome analytics.
“The human microbiome plays a transformative role in healthcare,” said Anuradha Acharya, Founder and CEO of Mapmygenome. “This acquisition accelerates our entry into the North American market and significantly deepens our scientific expertise in metagenomics, transcriptomics, and targeted metabolomics. It aligns with our broader strategy of growth through targeted acquisitions ahead of our upcoming listing on the Indian stock market.”
Microbiome Insights will continue to operate independently as a Contract Research Organization (CRO), providing world-class microbiome sequencing services. Meanwhile, Mapmygenome will expand its AI-driven genomics and microbiome offerings to North America, giving healthcare providers and research organizations access to holistic, integrated precision health solutions.
Malcolm Kendall, CEO of Microbiome Insights, added: “Joining forces with Mapmygenome allows us to scale our impact and offer even greater value to our global clientele. Combining their advanced genomics and AI capabilities with our deep expertise in microbiome science sets the stage for transformative innovation in health and research.”
Mapmygenome Global Growth Roadmap
While financial terms of the deal were not disclosed, the acquisition is part of Mapmygenome’s global growth roadmap, focusing on integrated health solutions powered by AI, big data, and bioinformatics.
Maymygenome harnesses AI-driven genomic and microbiome testing to deliver personalized health solutions, with offerings like at-home DNA tests for proactive health and longevity. For healthcare providers, their diagnostic genomic tests are conducted in a CAP-accredited lab, ensuring high accuracy, complemented by genetic counseling.
